Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9994852 | 0.87 | STS (0.47) | KMT2AMEN1USP30STS | |
| SCHEMBL9995101 | 0.85 | GPR119 (0.46) | GPR119KMT2AMEN1USP30NAMPT | |
| SCHEMBL9994907 | 0.83 | NOTUM (0.39) | — | |
| SCHEMBL742853 | 0.78 | STS (0.47) | KMT2AMEN1USP30STS | |
| SCHEMBL739287 | 0.78 | ALDH1A1 (0.44) | GPR119KMT2AMEN1USP30 | |
| SCHEMBL742792 | 0.77 | MEN1 (0.47) | KMT2AMEN1USP30STS | |
| SCHEMBL3407971 | 0.76 | CYP3A4 (0.40) | GPR119KMT2AMEN1 | |
| SCHEMBL3181373 | 0.75 | GPR119 (0.56) | GPR119KMT2AMEN1STS | |
| SCHEMBL6630324 | 0.73 | KMT2A (0.62) | GPR119KMT2AMEN1USP30 | |
| SCHEMBL29120062 | 0.72 | GPR119 (0.52) | GPR119KMT2AMEN1USP30NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | GPR119 16/4885KMT2A 1685/4885MEN1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.